Search results for "Immunization."

showing 10 items of 308 documents

Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months

2016

Up to 80% of the cost of vaccination programmes is due to the cold chain problem (that is, keeping vaccines cold). Inexpensive, biocompatible additives to slow down the degradation of virus particles would address the problem. Here we propose and characterize additives that, already at very low concentrations, improve the storage time of adenovirus type 5. Anionic gold nanoparticles (10−8–10−6 M) or polyethylene glycol (PEG, molecular weight ∼8,000 Da, 10−7–10−4 M) increase the half-life of a green fluorescent protein expressing adenovirus from ∼48 h to 21 days at 37 °C (from 7 to >30 days at room temperature). They replicate the known stabilizing effect of sucrose, but at several orders of…

0301 basic medicineSucroseSucroseTime FactorsvirusesGeneral Physics and AstronomyMetal Nanoparticles02 engineering and technologyvaccinationsvaccine storagePolyethylene Glycolschemistry.chemical_compoundMiceImmunogenicity VaccineDrug StabilityModelsAdenovirus Vaccinesvaccineta318ta317MultidisciplinaryChemistryImmunogenicityadenoviruksetQadenovirus021001 nanoscience & nanotechnologyImmunogenicityOrders of magnitude (mass)Cold Temperaturevaccine; adenovirus; additives; nanoparticlesInfectious DiseasesColloidal goldModels Animaladditives0210 nano-technologyInfectionBiotechnologyHalf-LifeScienceDrug StorageBioengineeringPolyethylene glycolModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyArticleVaccine RelatedExcipients03 medical and health sciencesPEG ratioAnimalsThermal stabilityChromatographyAnimalPreventionRational designta1182General ChemistryBiologicalVirology030104 developmental biologyadenovirusesFeasibility StudiesImmunizationnanoparticlesGoldVaccine
researchProduct

Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.

2017

Breaking tolerance is crucial for effective tumor immunotherapy. We showed that vaccines containing tumor-associated human MUC1 glycopeptides induce strong humoral antitumor responses in mice. The question remained whether such vaccines work in humans, in systems where huMUC1 is a self-antigen. To clarify the question, mice transgenic in expressing huMUC1, mimicking the self-tolerant environment, and wild-type mice were vaccinated with a synthetic vaccine. This vaccine comprised STn and Tn antigens bound to a MUC1 tandem repeat peptide coupled to tetanus toxoid. The vaccine induced strong immune responses in wild-type and huMUC1-transgenic mice without auto-aggressive side effects. All anti…

0301 basic medicineSynthetic vaccinemedicine.medical_treatmentBreast NeoplasmsMice TransgenicBiology01 natural sciencesBiochemistryCancer Vaccines03 medical and health sciencesImmune systemAntigenCancer immunotherapyDrug DiscoverymedicineTetanus ToxoidAnimalsHumansAntigens Tumor-Associated CarbohydrateGeneral Pharmacology Toxicology and PharmaceuticsPharmacologyVaccines Synthetic010405 organic chemistryTetanusOrganic ChemistryMucin-1ToxoidImmunotherapymedicine.diseaseVirologyPeptide Fragments0104 chemical sciencesMice Inbred C57BL030104 developmental biologyImmunizationImmunologyMCF-7 CellsMolecular MedicineFemaleImmunizationChemMedChem
researchProduct

Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells

2017

Designing of CD8 T cell vaccines which would provide protection against tumors is still considered a great challenge in immunotherapy. Here we show a robust potential of a cytomegalovirus (CMV) vector expressing the NKG2D ligand RAE-1γ as CD8 T cell-based vaccine against malignant tumors. Immunization with the CMV vector expressing RAE-1γ delayed tumor growth or even provided complete protection against tumor challenge in both prophylactic and therapeutic settings. Moreover, a potent tumor control in mice vaccinated with this vector can be further enhanced by blocking the immune checkpoints TIGIT and PD-1. Expression of RAE-1γ by the CMV vector potentiated expansion of KLRG1+ CD8 T cells wi…

0301 basic medicineTumor vaccine [RAE-1γ]medicine.medical_treatmentT cellImmunologyGenetic VectorsProgrammed Cell Death 1 ReceptorMelanoma ExperimentalCytomegalovirusEpitopes T-LymphocyteBiologyCD8-Positive T-LymphocytesCancer VaccinesArticleCMV vectorNKG2DImmunomodulation03 medical and health sciencesMiceImmune systemTIGITKLRG1+ CD8+ T cellsNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsHumansRAE-1γ : Tumor vaccineLectins C-TypeReceptors ImmunologicαTIGIT ; CMV vector ; KLRG1+ CD8+ T cells ; NKG2D ; RAE-1γ : Tumor vaccineBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Membrane ProteinsImmunotherapyNKG2DVirology3. Good healthKiller Cells NaturalDisease Models Animal030104 developmental biologymedicine.anatomical_structureImmunizationAnimals NewbornFemaleαTIGITImmunotherapyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.CD8
researchProduct

Immunization Status against Measles of Health-Care Workers Operating at Three Sicilian University Hospitals: An Observational Study

2019

Measles is a highly contagious vaccine-preventable disease (VPD) that also commonly affects health-care workers (HCWs). Measles immunization of HCWs was strongly recommended by international health authorities, in order to limit the spreading of the illness to susceptible patients and colleagues. An observational study, evaluating the immunization and vaccination status against measles of HCWs working at three Sicilian university hospitals, was conducted. All subjects not completely immune (vaccinated with only one dose in their lifetime), not immune (not vaccinated or not naturally immunized), and with an unknown immunization status were considered not immunized. Among HCWs operating in th…

0301 basic medicinehealth care facilities manpower and servicesanimal diseases030106 microbiologyImmunologyeducationlcsh:Medicinechemical and pharmacologic phenomenaDiseaseSettore MED/42 - Igiene Generale E ApplicataMeaslesArticle03 medical and health sciences0302 clinical medicineEnvironmental healthDrug DiscoveryHealth careHealth-care personnel Vaccine hesitancy Vaccine-preventable diseasemedicinePharmacology (medical)vaccine-preventable disease030212 general & internal medicinePharmacologybusiness.industrylcsh:RInternational healthhealth-care personnelbiochemical phenomena metabolism and nutritionmedicine.diseaseUniversity hospitalVaccinationInfectious DiseasesImmunizationHealth-care personnel; Vaccine hesitancy; Vaccine-preventable diseasebacteriavaccine hesitancyObservational studybusinessVaccines
researchProduct

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

2019

ABSTRACT HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of generating durable and specific immunity against these HPV16 antigens hold great promise to achieve long-term disease control. Here we show in mice that HPV16 E7 RNA-LPX, an intravenously administered cancer vaccine based on immuno-pharmacologically optimized antigen-encoding mRNA, efficiently primes and expands antigen-specific effector and memory CD8+ T cells. HPV-positive TC-1 and C3 tumors of immunized mice are heavily infiltrated with ac…

0301 basic medicinelcsh:Immunologic diseases. AllergyT cellImmunologyhpv16-positive malignancieslcsh:RC254-282t cell memoryhpv 16 rna-lpx03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunology and AllergyCytotoxic T cellMedicineOriginal Researchbusiness.industryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologymedicine.anatomical_structureOncologyImmunization030220 oncology & carcinogenesisCancer researchCancer vaccinebusinesscancer vaccinelcsh:RC581-607CD8e7OncoImmunology
researchProduct

Attitudes and perception of healthcare workers concerning influenza vaccination during the 2019/2020 season: A survey of sicilian university hospitals

2020

Influenza is an infectious disease with a high impact on the population in terms of morbidity and mortality, but despite International and European guidelines, vaccination coverage rates among healthcare workers (HCWs) remain very low. The aim of the present study was to evaluate influenza vaccination adherence in the three Sicilian University Hospitals of Catania, Messina, and Palermo and to understand the attitudes and perceptions of vaccinated healthcare workers and the main reasons for vaccination refusal. A cross-sectional survey through a self-administered questionnaire was conducted during the 2019/2020 influenza season. Overall, 2356 vaccinated healthcare workers answered the questi…

0301 basic medicinemedicine.medical_specialtyInfluenza vaccineImmunologyPopulationlcsh:MedicineArticle03 medical and health sciences0302 clinical medicineDrug DiscoveryHealth careMedicineHealthcare workersPharmacology (medical)030212 general & internal medicineAdherence; Attitudes; Flu vaccination; Healthcare workers; Influenza vaccine; RefusalFlu vaccinationeducationAdverse effectPharmacologyeducation.field_of_studybusiness.industryInfluenza vaccinePublic healthlcsh:Rvirus diseasesRefusalVaccination RefusalVaccination030104 developmental biologyInfectious DiseasesImmunizationAttitudeAdherenceFamily medicineAttitudesHealthcare workerbusiness
researchProduct

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets

2021

Infectious diseases are an important consideration in autoimmune conditions such as multiple sclerosis. Infective episodes may trigger relapses and significantly deteriorate the course of the disease. Some immunotherapies may cause increased rates of infection-related adverse events. Thus, infection and vaccine-related issues should be included in the individualized patient-specific treatment strategy and counseling before starting therapy and regularly on treatment. Clinical and epidemiological studies as well as pharmacovigilance data repeatedly demonstrated the safety of the great majority of vaccines in multiple sclerosis patients. Moreover, studies have shown that vaccinations with kil…

0301 basic medicinemedicine.medical_specialtyMedizincladribine tabletsDiseaseReviewimmunizationmultiple sclerosis1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineNatalizumabInternal medicinevaccinePharmacovigilancemedicineddc:610CladribineAdverse effectRC346-42911 Medical and Health SciencesPharmacologybusiness.industryMultiple sclerosisCOVID-19Vaccine efficacymedicine.diseaseVaccinationCoronavirus030104 developmental biologyNeurology1107 ImmunologyNeurology (clinical)Neurology. Diseases of the nervous systembusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct

Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.

2021

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early 2020 soon led to the global pandemic of Coronavirus Disease 2019 (COVID-19). Since then, the clinical and scientific communities have been closely collaborating to develop effective strategies for controlling the ongoing pandemic. The game-changing fields of recent years, nanotechnology and nanomedicine have the potential to not only design new approaches, but also to improve existing methods for the fight against COVID-19. Nanomaterials can be used in the development of highly efficient, reusable personal protective equipment, and antiviral nano-coatings in public settings could prevent the spread of SAR…

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pharmaceutical ScienceNanotechnology02 engineering and technologyReview Article03 medical and health sciencesPandemicDiagnosisMedicineHumansNanotechnologyPandemics030304 developmental biology0303 health sciencesbusiness.industrySARS-CoV-2COVID-19021001 nanoscience & nanotechnologyClinical trialNanovaccineImmunizationNanomedicineImmunizationNanocarriers0210 nano-technologybusinessJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Urology practice during the COVID-19 vaccination campaign

2021

Introduction: The current scenario of the COVID-19 pandemic is significantly different from that of the first, emergency phase. Several countries in the world are experiencing a second, or even a third, wave of contagion, while awaiting the effects of mass vaccination campaigns. The aim of this report was to provide an update of previously released recommendations on prioritization and restructuring of urological activities. Methods: A large group of Italian urologists directly involved in the reorganization of their urological wards during the first and second phase of the pandemic agreed on a set of updated recommendations for current urology practice. Results: The updated recommendations…

2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronaviru030232 urology & nephrologycoronavirusmedicine.disease_causesurgery03 medical and health sciences0302 clinical medicinevaccinePandemicmedicineHumansOriginal Research Articlecoronavirus; COVID-19; pandemic; vaccine; urology; clinical practice guidelines; surgery; endourologyurologyPandemicsCoronavirusbusiness.industryImmunization ProgramsSARS-CoV-2pandemicendourologyCOVID-19General MedicineVirologySmart communication (SC173–SC181) Urinary stones: timing and assessmentVaccination030220 oncology & carcinogenesisEmergency medicineUrologic Surgical ProceduresCOVID-19; Coronavirus; clinical practice guidelines; endourology; pandemic; surgery; urology; vaccinebusinessclinical practice guidelinesclinical practice guideline
researchProduct

Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation.

2011

Reactivated infections with herpes family-related cytomegalovirus, Epstein–Barr virus and varicella zoster virus are serious and sometimes life-threatening complications for patients undergoing allogeneic hematopoietic stem cell transplantation. The pathogenesis of these infections critically involves the slow and inefficient recovery of antiviral T-cell immunity after transplantation. Although efficient drugs to decrease viral load during this vulnerable period have been developed, long-term control of herpes viruses and protection from associated diseases require the sufficient reconstitution of virus-specific memory T cells. To heal the deficiency by immunotherapeutic means, numerous re…

Adoptive cell transfervirusesmedicine.medical_treatmentT-LymphocytesImmunologyHematopoietic stem cell transplantationBiologyAdaptive Immunitymedicine.disease_causeVirusImmunitymedicineImmunology and AllergyAnimalsHumansVaricella zoster virusHematopoietic Stem Cell TransplantationHerpesviridae InfectionsVirologyEpstein–Barr virusImmunity InnateTransplantationOncologyImmunologyImmunizationViral loadImmunotherapy
researchProduct